According to filings with the U.S. Securities and Exchange Commission, Corner Therapeutics is raising up to $50,941,210.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Nick Seaver played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Corner Therapeutics
Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies even for the most difficult to treat diseases.

To learn more about Corner Therapeutics, visit http://cornertx.com/

Contact:
Nick Seaver, Chief Financial Officer
617-701-7014
https://www.linkedin.com/in/nicholas-seaver-9843793/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.